Clinical trials: Dosimetry
Gastroenteropancreatic Neuroendocrine Tumors
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
The purpose of this study is to assess the safety and tolerability of 68Ga-OPS202 used for the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP NETs).
- Trial name
- NCT02162446
- Testing
- satoreotide trizoxetan
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Ipsen
Lymphoma, Follicular
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Patients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131 Tositumomab. Pharmacokinetic data for the primary endpoint analysis will be derived from testing done on blood samples drawn at 12 timepoints…
- Trial name
- NCT00315731
- Testing
- Follicular Lymphoma
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Ankylosing Spondylitis
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
This was a monocentric, open label, Phase I-IIa study. Eligible patients who signed the ICF received two single intravenous (IV) bolus of the imaging agent 99mTc-rhAnnexin V-128.
- Trial name
- NCT02328027
- Testing
- 99mTc-rhAnnexin V-128
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Advanced Accelerator Applications
HCC, Cancer of Liver
Low-dose Y90 Treatment Planning for HCC
The study proposes low-dose Y90 microspheres for therapy planning of HCC, as an alternative to Technetium (99mTc) albumin aggregated (MAA), to be a bioidentical therapeutic Y90 surrogate marker to better predict and thus achieve…
- Conditions
- HCC, Cancer of Liver, Cancer
- Trial name
- NCT04172714
- Testing
- SIR-Spheres microspheres
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics (PD), and efficacy of the targeted radionuclide therapeutic CAM-H2 in patients…
- Trial name
- NCT04467515
- Testing
- CAM-H2
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Precirix
Graves' Disease
Radioactive Iodide Therapy for Pediatric Graves' Disease
The investigators hypothesize that 131I is an effective therapy for children with Graves' Disease (GD) and will not be associated with long-term cancer risks when used in older children, but may be associated with excessive…
- Trial name
- NCT01269749
- Testing
- RAI treatment, ATD Group
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Florida
Primary Malignant Liver Neoplasm
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors
This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors .
- Trial name
- NCT03109262
- Testing
- Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Stanford University